Cyclapen-W: Uses, Effects, Mechanism of Action
Table of Contents
- Introduction
- Chemical Composition and Structure
- Classification
- Mechanism of Action
- Pharmacokinetics
- Therapeutic Uses
- Side Effects and Contraindications
- Drug Interactions
- Brand Names and Synonyms
- Chemical Properties
- Regulatory Status
- Comparative Efficacy
- Development and Synthesis
- Clinical Studies and Trials
- Resistance
- Resources and References
- Further Reading
Introduction
Cyclapen-W is a semi-synthetic aminopenicillin antibiotic that belongs to the beta-lactam class of antibiotics. It is a trade name for the drug cyclacillin, which is used to treat various bacterial infections. Cyclapen-W works by inhibiting bacterial cell wall synthesis, leading to the death of susceptible bacteria.
Chemical Composition and Structure
The molecular formula of
Cyclapen-W (cyclacillin) is C
15H
23N
3O
4S. It has a molecular weight of 341.4 g/mol and an exact mass of 341.139 Da. The SMILES representation of cyclacillin is
CC1(C)SC2C(NC(=O)C(N)C2C(=O)NC2CCCCC2)C1C(=O)O.
Classification
Cyclapen-W belongs to the following classes of antibiotics:
- Aminopenicillin antibiotics
- Beta-lactam antibiotics
- Semi-synthetic antibiotics
Mechanism of Action
Cyclapen-W exhibits bactericidal properties by binding to penicillin-binding proteins (PBPs) in the bacterial cell wall. This binding inhibits the synthesis of the peptidoglycan layer, which is essential for maintaining the structural integrity of the bacterial cell wall. The weakened cell wall leads to cell lysis and death of the susceptible bacteria [1].
armacokinetics”> armacokinetics/”>Ph armacokinetics
After oral administration, Cyclapen-W is rapidly absorbed from the gastrointestinal tract. It is widely distributed throughout the body, including in the lungs, kidneys, and skin. The drug undergoes partial metabolism in the liver and is primarily excreted unchanged in the urine [2].
Therapeutic Uses
Cyclapen-W is indicated for the treatment of various bacterial infections caused by susceptible organisms, such as:
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Dental infections
The spectrum of activity of Cyclapen-W includes both gram-positive and gram-negative bacteria [1].
Side Effects and Contraindications
Common side effects of Cyclapen-W include:
- Gastrointestinal disturbances (nausea, vomiting, diarrhea)
- Allergic reactions (rash, itching, hives)
- Headache
- Fatigue
Severe adverse reactions, such as anaphylaxis, may occur in some individuals. Cyclapen-W is contraindicated in patients with a known allergy to penicillin or any component of the formulation.
Drug Interactions
Cyclapen-W may interact with other medications, such as:
- Probenecid (decreases renal excretion of Cyclapen-W)
- Oral contraceptives (reduced efficacy)
- Methotrexate (increased toxicity)
Brand Names and Synonyms
Cyclapen-W is marketed under various trade names, including:
- Cyclapen
- Vastcillin
- Calthor
- Citosarin
- Orfilina
- Syngacillin
- Ultracillin
- Vipicil
- Wyvital
Other synonyms for cyclacillin include Ciclacillin (INN), Cyclacillin (USAN), WY-4508, and NSC-88789.
Chemical Properties
Cyclapen-W is a white to off-white crystalline powder. It is slightly soluble in water and soluble in methanol and ethanol. The drug should be stored at room temperature, protected from light and moisture.
Regulatory Status
Cyclapen-W has been approved by various health authorities, such as the U.S. Food and Drug Administration (FDA), for the treatment of bacterial infections. It is available by prescription only.
Comparative Efficacy
Studies have shown that Cyclapen-W has similar efficacy to other antibiotics in the aminopenicillin class, such as ampicillin and amoxicillin, in treating susceptible bacterial infections [3].
Development and Synthesis
Cyclapen-W was developed as a semi-synthetic derivative of penicillin. The synthesis process involves the acylation of 6-aminopenicillanic acid (6-APA) with D-(-)-α-aminocyclohexanecarboxylic acid, followed by purification steps.
Clinical Studies and Trials
Several clinical trials have been conducted to evaluate the efficacy and safety of Cyclapen-W in treating various bacterial infections. These studies have demonstrated the effectiveness of Cyclapen-W in eradicating susceptible pathogens and improving clinical outcomes.
Resistance
Bacterial resistance to Cyclapen-W can occur through various mechanisms, such as the production of beta-lactamases, alterations in penicillin-binding proteins, and efflux pumps. Strategies to overcome resistance include the use of beta-lactamase inhibitors and the development of new antibiotics with modified structures.
Resources and References
Key scientific publications and databases for further information on Cyclapen-W include:
- DrugBank
- KEGG
- ChEMBL
- HMDB
- Inxight Drugs
Further Reading
For more detailed information on Cyclapen-W and related topics, readers can refer to:
- Peer-reviewed articles
- Medical textbooks
- Official drug information websites
